Diaccurate receives support from Bpifrance to conduct its DIACC2020 Program on the development of new payloads for antibody-drug conjugates (ADCs)

• The DIACC2020 platform aims to develop a new generation of cytotoxic compounds to be conjugated to therapeutic antibodies
• The Program stems from the unique properties of its proprietary compound DIACC2010, developed by Diaccurate for the treatment of Acute Myeloid Leukemia

Diaccurate, a French biotechnology company specialized in the development of new therapies in oncology, today announced it received from Bpifrance a grant termed “Aide à l’Innovation” to support its DIACC2020 Program aiming to establish the preclinical proof-of-concept of its sole-in-class molecule DIACC2010 as a next-generation payload for ADCs, for the treatment of solid and hematologic tumors.